Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 93 of 95, showing 5 Applications out of 471 total, starting on record 461, ending on 465

# Protocol No Study Title Investigator(s) & Site(s)

461.

ECCT/10/05/02   AERAS-402
    A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter, Proof-of-concept Study to Evaluate the Safety and Efficacy of AERAS-402 in BCG-vaccinated, HIV-uninfected Infants Without Evidence of Tuberculosis   
Principal Investigator(s)
1. Dr Videlis Nduba
2. Dr Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI-CDC
 
View

462.

ECCT/10/03/03   High-Dose Fluconazole Treatment in AIDS-Associated CM
    A5225/HiFLAC: A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

463.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
View

464.

ECCT/09/06/02  
    A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy   plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual   Transmission of HIV-1 In Serodiscordant Couples   
Principal Investigator(s)
1. Lisa Ann Mills
Site(s) in Kenya
Kisumu, Kenya
 
View

465.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
View